

Cover Story
It's possible that molecular testing is doing a lot of good, pinpointing cancer therapies that are most likely (or least likely) to work.
In Brief


Trending Stories
- Trump backs off the 100% pharma tariffs ultimatum
- Sakaguchi, Ramsdell, Rudensky win Crafoord Prize for discoveries in immune regulation
- Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research
- White House announces “TrumpRx,” a new prescription drug website
- U.S. government shuts down
Impact on NCI uncertain as administration threatens more RIFs - Pulitzer-winning healthcare reporter Laurie McGinley on her shift to advocacy work with PACR